Personalized Medicine? An Update on Warfarin (Coumadin) Labeling

U.S. Food and Drug Administration. FDA News. FDA approves updated warfarin (Coumadin) prescribing information. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html. Accessed August 22, 2007.

Schalekamp T. , Brassé B.P. , Roijers J.F.M. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006; 80(1): 13–22.

Wadelius M. , Chen L.Y. , Eriksson N. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007; 127(1): 23–34.

Wood S. New warfarin labeling reminds physicians about genetic tests to help guide initial warfarin dosing. http://www.theheart.org/article/807123.do. Accessed August 28, 2007.

Yin T. , Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res. 2007; 120(1): 1–10.

U.S. Food and Drug Administration. Critical Path Initiative. http://www.fda.gov/oc/initiatives/criticalpath/. Accessed August 27, 2007.